Skip to content
Menu

Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $625

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $590 to $625.

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $590 to $625.

Read at benzinga.com

← All stock news